4Kaplan EM.Efficacy of venlafaxine in patients with major depressive disorder who have unsustained of on response to selective serotonin reuptake inhibitors:an open-label,uncontrolled study.Clin Ther,2002,24(7):1194-1120.
2[2]Judge R, Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression. J Clin Psychiatry,2001,62( 11 ):888 ～ 893
3[3]Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained of on response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther,2002, 24(7): 1194～1200
4[4]Rusolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reupatake inhibitors. Acta Psychiatr Scand Suppl, 2002, (415) : 24 ～30
5[6]Wellingon K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs, 2001, 15 (8) : 643 ～669
6[7]Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacol, 2002, 17(6) : 273 ～280
7[8]Momtgomery SA, Mahe V, Hardiquet V, et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and longterm treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol, 2002, 22(6) : 561 ～567
8[9]Ables AZ, Baughman OL. Antidepressants: update on new agents and indications. Am Fam Physician, 2003, 67 (3) : 547 ～ 554
9[10]Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry, 2003, 160 (7) : 1252～1262
10[11]Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord, 2003, 5(2) : 85～97
